Advertisement
Advertisement
U.S. markets open in 8 hours 2 minutes
S&P Futures
3,864.75 +16.50 (+0.43%) Dow Futures
31,135.00 +122.00 (+0.39%) Nasdaq Futures
11,945.00 +64.75 (+0.55%) Russell 2000 Futures
1,737.80 +9.20 (+0.53%) Crude Oil
99.34 +0.81 (+0.82%) Gold
1,745.10 +8.60 (+0.50%)
Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 62.34 |
| Open | 62.62 |
| Bid | 0.00 x 3000 |
| Ask | 0.00 x 3100 |
| Day's Range | 62.16 - 62.88 |
| 52 Week Range | 57.17 - 74.12 |
| Volume | |
| Avg. Volume | 7,972,616 |
| Market Cap | 78.683B |
| Beta (5Y Monthly) | 0.38 |
| PE Ratio (TTM) | 17.52 |
| EPS (TTM) | 3.58 |
| Earnings Date | Jul 27, 2022 - Aug 01, 2022 |
| Forward Dividend & Yield | 2.92 (4.68%) |
| Ex-Dividend Date | Jun 14, 2022 |
| 1y Target Est | 69.21 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
32% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for GILD
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Gilead Sciences, Inc.Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.RatingFair ValueEconomic Moat24 days agoMorningstar
- Zacks
Q2 Earnings: Energy and What Else?
Expectations are low for this earnings season. Will companies surprise the Street?
- Zacks
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $62.34, moving -0.03% from the previous trading session.
- Motley Fool
Is Gilead Sciences' Dividend Safe?
Biotech giant Gilead Sciences (NASDAQ: GILD) has a lot going its way, including the company's juicy dividend yield of 4.7%. With this backdrop in mind, let's consider whether Gilead Sciences' dividend is safe. Gilead Sciences has been highly successful in the market for COVID-19 therapies thanks to its antiviral Veklury.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
